Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program PR Newswire WALTHAM, Mass., Dec. 10, 2024 -- SIGNAL-AA demonstrated encouraging...
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Nov. 7, 2024 -- Bempikibart Phase 2 topline results in atopic dermatitis (AD) and...
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference PR Newswire WALTHAM, Mass., Nov. 5, 2024 WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.28 | 8.97435897436 | 3.12 | 3.57 | 3.015 | 184841 | 3.16487589 | CS |
4 | 0.11 | 3.34346504559 | 3.29 | 4.1499 | 2.99 | 334128 | 3.4422146 | CS |
12 | -43.6 | -92.7659574468 | 47 | 51.2569 | 2.99 | 381092 | 8.84894981 | CS |
26 | -26.21 | -88.5173927727 | 29.61 | 53.79 | 2.99 | 227045 | 17.77049457 | CS |
52 | -12.84 | -79.0640394089 | 16.24 | 53.79 | 2.99 | 163890 | 18.5051898 | CS |
156 | -12.84 | -79.0640394089 | 16.24 | 53.79 | 2.99 | 163890 | 18.5051898 | CS |
260 | -12.84 | -79.0640394089 | 16.24 | 53.79 | 2.99 | 163890 | 18.5051898 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.